Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling

被引:0
作者
Farnaz Khodabakhsh
Parnaz Merikhian
Mohammad Reza Eisavand
Leila Farahmand
机构
[1] AJA University of Medical Sciences,Department of Genetics and Advanced Medical Technology, Medical Biotechnology Research Center, Faculty of Medicine
[2] Motamed Cancer Institute,Recombinant Proteins Department, Breast Cancer Research Center
[3] ACECR,undefined
来源
Cancer Cell International | / 21卷
关键词
Angiogenesis; VEGF; VEGFR; MUC1; Cancer; Targeted therapy;
D O I
暂无
中图分类号
学科分类号
摘要
VEGF and its receptor family (VEGFR) members have unique signaling transduction system that play significant roles in most pathological processes, such as angiogenesis in tumor growth and metastasis. VEGF-VEGFR complex is a highly specific mitogen for endothelial cells and any de-regulation of the angiogenic balance implicates directly in endothelial cell proliferation and migration. Moreover, it has been shown that overexpressing Mucin 1 (MUC1) on the surface of many tumor cells resulting in upregulation of numerous signaling transduction cascades, such as growth and survival signaling pathways related to RTKs, loss of cell-cell and cell-matrix adhesion, and EMT. It promotes gene transcription of pro-angiogenic proteins such as HIF-1α during periods of oxygen scarcity (hypoxia) to enhance tumor growth and angiogenesis stimulation. In contrast, the cytoplasmic domain of MUC1 (MUC1-C) inhibits apoptosis, which in turn, impresses upon cell fate. Besides, it has been established that reduction in VEGF expression level correlated with silencing MUC1-C level indicating the anti-angiogenic effect of MUC1 downregulation. This review enumerates the role of MUC1-C oncoprotein and VEGF in angiogenesis and metastasis and describes several signaling pathways by which MUC1-C would mediate the pro-angiogenic activities of cancer cells.
引用
收藏
相关论文
共 132 条
[41]  
Jalili N(2004)The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts J Biol Chem 279 35458-13792
[42]  
Singh PK(2003)Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress J Biol Chem 278 607-1428
[43]  
Hollingsworth MA(2017)MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer Expert Rev Anticancer Ther 17 257-471
[44]  
Obermair A(2007)Mucin 1 oncoprotein blocks hypoxia-inducible factor 1α activation in a survival response to hypoxia J Biol Chem 282 94-361
[45]  
Zhou Y(1999)Cancer multidrug resistance Nat Biotechnol 17 e51-92
[46]  
Rajabi H(2013)MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes Oncogenesis 2 7013-706
[47]  
Kufe D(2009)MUC1-C oncoprotein functions as a direct activator of the nuclear factor-κB p65 transcription factor Cancer Res 69 42248-264
[48]  
Gendler SJ(2011)MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-κB p65 and binding to cytokine promoters importance of extracellular domain J Biol Chem 286 874-265
[49]  
Carson DD(2009)Mucins in cancer: function, prognosis and therapy Nat Rev Cancer 9 737-871
[50]  
Kitamoto S(2018)Significant role of MUC1 in development of resistance to currently existing anti-cancer therapeutic agents Curr Cancer Drug Targets 18 167-4853